Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-01-24 Capital/Financing Update
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Marketing materials - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed description of a firm commitment private placement of units by Tetra Bio-Pharma Inc., including terms such as the number of units, price, overallotment option, subscription warrants, use of proceeds, and placement agent remuneration. It is a capital raising document describing the offering of securities and related terms. There is no indication that this is a full financial report, audit, or regulatory filing. The document is not an announcement of a report publication but the actual offering details. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4362 characters, which is sufficient for a detailed placement summary but not a full annual or interim report.
2020-01-24 English
News release - English.pdf
Regulatory Filings
2020-01-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has been granted two OTC Drug Identification Numbers (DIN) by Health Canada for products under its TERPACAN™ brand. It discusses product approvals, expected launch timelines, market information, and forward-looking statements. There is no indication that this is a financial report, regulatory filing, or any other formal filing type. It is a corporate announcement about product approval and commercialization plans, which fits best under the category of a general Regulatory Filing (RNS) as it does not match any other specific filing category such as earnings release, capital update, or management information.
2020-01-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received a favorable Letter of Advice from the US FDA regarding the development of their drug QIXLEEF. It discusses regulatory feedback, market potential, and forward-looking statements about the drug's development and approval prospects. There are no financial statements, earnings data, or detailed financial analysis present. The document is an update on regulatory and development progress rather than a formal financial report or filing. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is also not a management or board change announcement, nor a legal proceeding or capital update. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit any other specific category.
2020-01-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received a favorable Letter of Advice from the US FDA regarding the development of their drug QIXLEEF. It discusses regulatory feedback, development plans, and market potential but does not contain financial statements, detailed financial performance, or comprehensive report data. It is not a full financial report, earnings release, or management discussion. The document is an update on regulatory and development progress, which fits best under a general regulatory announcement category. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or attestation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-01-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on regulatory activities related to drug approval processes with the U.S. FDA and Health Canada. It discusses submissions, review phases, and anticipated timelines but does not contain financial statements, detailed financial data, or comprehensive report content. It is an announcement of ongoing regulatory progress rather than a full report or detailed filing. The document length is moderate (5892 characters) but the content is clearly an update on regulatory activities, not a formal report or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-01-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.